{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:31:41Z","timestamp":1782901901159,"version":"3.54.5"},"reference-count":29,"publisher":"Touch Medical Media, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"abstract":"<p\/>","DOI":"10.17925\/hi.2021.15.1.2","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T12:10:52Z","timestamp":1628770252000},"page":"2","source":"Crossref","is-referenced-by-count":6,"title":["Update on Etripamil Nasal Spray for the At-home Treatment of Acute Paroxysmal Supraventricular Tachycardia"],"prefix":"10.17925","volume":"15","author":[{"given":"Gavin S","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, UK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiraj","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, UK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Go AS, Hlatky MA, Liu TI, et al. Contemporary burden and correlates of symptomatic paroxysmal supraventricular tachycardia.\n                      J Am Heart Assoc\n                      . 2018;7:e008759.","DOI":"10.1161\/JAHA.118.008759"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Khurshid S, Choi SH, Weng L, et al. Frequency of cardiac rhythm abnormalities in a half million adults.\n                      Circ Arrhythmia Electrophysiol\n                      . 2018;11:e006273.","DOI":"10.1161\/CIRCEP.118.006273"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Murman DH, McDonald AJ, Pelletier AJ, Camargo CA. U.S. emergency department visits for supraventricular tachycardia, 1993-2003.\n                      Acad Emerg Med\n                      . 2007;14:578\u201381.","DOI":"10.1197\/j.aem.2007.01.013"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Sacks NC, Cyr PL, Preib MT, et al. Healthcare resource use and expenditures in patients newly diagnosed with paroxysmal supraventricular tachycardia.\n                      Am J Cardiol\n                      . 2020;125:215\u201321.","DOI":"10.1016\/j.amjcard.2019.10.015"},{"key":"ref5","unstructured":"Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC\/AHA\/HRS Guideline for the management of adult patients with supraventricular tachycardia: Executive Summary: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.\n                      Circulation\n                      . 2016;133:e471\u2013505."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia.\n                      Eur Heart J\n                      . 2020;41:655\u2013720.","DOI":"10.1093\/eurheartj\/ehz467"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Smith GD, Fry MM, Taylor D, et al. Effectiveness of the Valsalva manoeuvre for reversion of supraventricular tachycardia.\n                      Cochrane Database Syst Rev\n                      . 2015;2015:CD009502.","DOI":"10.1002\/14651858.CD009502.pub3"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Mariaca AF, Valdueza JM, Gaebel C, Gomez-Choco M. Simultaneous transient global amnesia and right MCA stroke after Valsalva manoeuvre.\n                      BMJ Case Rep\n                      . 2017;2017:bcr2016218990.","DOI":"10.1136\/bcr-2016-218990"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Ungvari Z, Yabluchanskiy A, Tarantini S, et al. Repeated Valsalva maneuvers promote symptomatic manifestations of cerebral microhemorrhages: implications for the pathogenesis of vascular cognitive impairment in older adults.\n                      GeroScience\n                      . 2018;40:485\u201396.","DOI":"10.1007\/s11357-018-0044-9"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Walsh T, Clinch D, Costelloe A, et al. Carotid sinus massage \u2013 How safe is it?\n                      Age Ageing\n                      . 2006;35:518\u201320.","DOI":"10.1093\/ageing\/afl057"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"DiMarco JP, Sellers TD, Berne RM, et al. Adenosine: Electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia.\n                      Circulation\n                      . 1983;68:1254\u201363.","DOI":"10.1161\/01.CIR.68.6.1254"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Delaney B, Loy J, Kelly A. The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults.\n                      Eur J Emerg Med\n                      . 2011;18:148\u201352.","DOI":"10.1097\/MEJ.0b013e3283400ba2"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Alabed S, Sabouni A, Providencia R, et al. Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia.\n                      Cochrane Database Syst Rev\n                      . 2017;10:CD005154.","DOI":"10.1002\/14651858.CD005154.pub4"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Alboni P, Tomasi C, Menozzi C, et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia.\n                      J Am Coll Cardiol\n                      . 2001;37:548\u201353.","DOI":"10.1016\/S0735-1097(00)01128-1"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Lafuente-Lafuente C, Valembois L, Bergmann J-F, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.\n                      Cochrane Database Syst Rev\n                      . 2015;CD005049.","DOI":"10.1002\/14651858.CD005049.pub4"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Choe WC, Sundaram S, Boorman C, et al. High-density mapping of the slow pathway in a patient with atrioventricular nodal reentry given intranasal etripamil during the NODE-1 study.\n                      Heart Rhythm Case Reports\n                      . 2017;3:479\u201382.","DOI":"10.1016\/j.hrcr.2017.07.011"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Orejarena LA, Vidaillet H, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population.\n                      J Am Coll Cardiol\n                      . 1998;31:150\u20137.","DOI":"10.1016\/S0735-1097(97)00422-1"},{"key":"ref18","unstructured":"United States Securities and Exchange Commission. Form S-1 \u2013 Registration Statement under the Securities Act of 1933. 2019. Available at: www.sec.gov\/Archives\/edgar\/data\/0001408443\/000104746919002213\/a2238338zs-1.htm (accessed 14 April 2021)."},{"key":"ref19","unstructured":"Milestone Pharmaceuticals. Milestone announces positive phase 1 data for MSP-2017; supports advancement into phase 2 in PSVT patients. 2014. Available at: https:\/\/investors.milestonepharma.com\/news-releases\/news-release-details\/milestone-announces-positive-phase-1-data-msp-2017-supports (accessed 20 April 2021)"},{"key":"ref20","unstructured":"United States Securities and Exchange Commission. Form 10-Q \u2013 Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, for the Quarterly Period Ended September 30, 2020. 2020. Available at: www.sec.gov\/Archives\/edgar\/data\/1408443\/000155837020013774\/mist-20200930x10q.htm (accessed 14 April 2021)."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Stambler BS, Dorian P, Sager PT, et al. Etripamil nasal spray for rapid conversion of supraventricular tachycardia to sinus rhythm.\n                      J Am Coll Cardiol\n                      . 2018;72:489\u201397.","DOI":"10.1016\/j.jacc.2018.04.082"},{"key":"ref22","unstructured":"ClinicalTrials.gov. Efficacy and safety of intranasal MSP-2017 (Etripamil) for the conversion of PSVT to sinus rhythm (NODE-1). ClinicalTrials.gov Identifier: NCT02296190. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02296190 (accessed 9 July 2021)."},{"key":"ref23","unstructured":"ClinicalTrials.gov. Efficacy and safety of etripamil for the termination of spontaneous PSVT. NODE 301 [Part 1 and Part 2 (The RAPID Study)]. ClinicalTrials.gov Identifier: NCT03464019. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03464019 (accessed 20 May 2021)."},{"key":"ref24","unstructured":"Stambler BS, Plat F, Sager PT, et al. Etripamil nasal spray for acute termination of spontaneous episodes of paroxysmal supraventricular tachycardia (NODE-301).\n                      Heart Rhythm\n                      . 2020;17:1200. Abstract D-LBCT01-01."},{"key":"ref25","unstructured":"Milestone Pharmaceuticals. Milestone Pharmaceuticals announces first patient enrolled in RAPID, a pivotal phase 3 study of etripamil in PSVT. 2020. Available at: https:\/\/investors.milestonepharma.com\/news-releases\/news-release-details\/milestone-pharmaceuticals-announces-first-patient-enrolledrapid (accessed 20 April 2021)"},{"key":"ref26","unstructured":"ClinicalTrials.gov. Safety study of intranasal etripamil for the termination of spontaneous episodes of paroxysmal supraventricular tachycardia (PSVT). NODE-302. ClinicalTrials.gov Identifier: NCT03635996. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03635996 (accessed 20 May 2021)."},{"key":"ref27","unstructured":"ClinicalTrials.gov. Safety study of etripamil nasal spray for patients with paroxysmal supraventricular tachycardia. NODE-303. ClinicalTrials.gov Identifier: NCT04072835. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04072835 (accessed 20 May 2021)."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Brachmann J, Lewalter T, Kuck KH, et al. Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry.\n                      Eur Heart J\n                      . 2017;38:1317-26.","DOI":"10.1093\/eurheartj\/ehx101"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Brugada J, Puigfel M, Mont L, et al. Radiofrequency ablation of anteroseptal, para-Hisian,and mid-septal accessory pathways using a simplified femoral approach.\n                      Pacing Clin Electrophysiol\n                      . 1998;21:735\u201341.","DOI":"10.1111\/j.1540-8159.1998.tb00131.x"}],"container-title":["Heart International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchcardio.com\/arrhythmia\/journal-articles\/update-on-etripamil-nasal-spray-for-the-at-home-treatment-of-acute-paroxysmal-supraventricular-tachycardia\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:58:27Z","timestamp":1764745107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchcardio.com\/arrhythmia\/journal-articles\/update-on-etripamil-nasal-spray-for-the-at-home-treatment-of-acute-paroxysmal-supraventricular-tachycardia\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"alternative-id":["HI.2021.15.1.2"],"URL":"https:\/\/doi.org\/10.17925\/hi.2021.15.1.2","relation":{},"ISSN":["2036-2579"],"issn-type":[{"value":"2036-2579","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}